Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.26302 http://scihub22266oqcxt.onion/10.1002/jmv.26302 32667699!7404948!32667699     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2021 ; 93 (2): 775-785 Nephropedia Template TP {{tp|p=32667699|t=2021. Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection |pdf=|usr=}}{{32667699}} gab.com Text Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32667699 #FOAvip Treatment options for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients >/=18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95% confidence interval [CI]: 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97-1.89). Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60-9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options. Twit Text FOAVip Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32667699 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32667699 #FOAvip English Wikipedia <ref>{{Cite pmid|32667699}}</ref> Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection #MMPMID32667699 Thoguluva Chandrasekar V; Venkatesalu B; Patel HK; Spadaccini M; Manteuffel J; Ramesh M J Med Virol 2021[Feb]; 93 (2): 775-785 PMID32667699show ga Treatment options for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients >/=18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95% confidence interval [CI]: 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97-1.89). Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60-9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options. |Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & derivatives[MESH] |Adrenal Cortex Hormones/*administration & dosage/adverse effects[MESH] |Alanine/administration & dosage/adverse effects/*analogs & derivatives[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects[MESH] |Antiviral Agents/*administration & dosage/adverse effects[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/mortality/pathology/*therapy/virology[MESH] |Drug Administration Schedule[MESH] |Drug Combinations[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/*administration & dosage/adverse effects[MESH] |Immunization, Passive[MESH] |Lopinavir/*administration & dosage/adverse effects[MESH] |Male[MESH] |Middle Aged[MESH] |Odds Ratio[MESH] |Ritonavir/*administration & dosage/adverse effects[MESH] |SARS-CoV-2/drug effects/pathogenicity[MESH] |Survival Analysis[MESH]Systematic review and meta-analysis of effectiveness of treatment opti(epmc).pdf DeepDyve Pubget Overpricing